- Home
- GBIO vs FLL Comparison
GBIO vs FLL Comparison
Compare GBIO & FLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBIO
- FLL
- Stock Information
- Founded
- GBIO 2016
- FLL 1987
- Country
- GBIO United States
- FLL United States
- Employees
- GBIO N/A
- FLL N/A
- Industry
- GBIO Biotechnology: Pharmaceutical Preparations
- FLL Hotels/Resorts
- Sector
- GBIO Health Care
- FLL Consumer Discretionary
- Exchange
- GBIO Nasdaq
- FLL Nasdaq
- Market Cap
- GBIO 145.5M
- FLL 170.4M
- IPO Year
- GBIO 2020
- FLL 1993
- Fundamental
- Price
- GBIO $2.44
- FLL $4.93
- Analyst Decision
- GBIO Buy
- FLL Buy
- Analyst Count
- GBIO 4
- FLL 2
- Target Price
- GBIO $7.50
- FLL $6.50
- AVG Volume (30 Days)
- GBIO 65.7K
- FLL 68.3K
- Earning Date
- GBIO 08-07-2024
- FLL 08-06-2024
- Dividend Yield
- GBIO N/A
- FLL N/A
- EPS Growth
- GBIO N/A
- FLL N/A
- EPS
- GBIO N/A
- FLL N/A
- Revenue
- GBIO $13,174,000.00
- FLL $274,988,000.00
- Revenue This Year
- GBIO $99.36
- FLL $26.61
- Revenue Next Year
- GBIO N/A
- FLL $13.32
- P/E Ratio
- GBIO N/A
- FLL N/A
- Revenue Growth
- GBIO 1397.05
- FLL 47.08
- 52 Week Low
- GBIO $0.86
- FLL $3.40
- 52 Week High
- GBIO $4.65
- FLL $5.98
- Technical
- Relative Strength Index (RSI)
- GBIO 47.29
- FLL 48.88
- Support Level
- GBIO $2.13
- FLL $4.86
- Resistance Level
- GBIO $2.49
- FLL $5.11
- Average True Range (ATR)
- GBIO 0.23
- FLL 0.17
- MACD
- GBIO -0.01
- FLL 0.01
- Stochastic Oscillator
- GBIO 38.27
- FLL 51.72
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
About FLL Full House Resorts Inc.
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins.